

Index

A

- ABMTHDC. *See* Autologous bone marrow transplant with high-dosage chemotherapy
- Academic Medical Center Consortium
 RAND Corporation cooperative effort, 234
- ACC. *See* American College of Cardiology
- Acknowledgments, 203-209
- ACP. *See* American College of Physicians
- ACPObserver, 227
- Acquired immunodeficiency syndrome. *See* AIDS
- Active approaches to changing physician behavior
 administrative approaches, 180-181, 197
 clinical peer influence, 183
 combining feedback and economic incentives, 186-187, 197
 continuous quality improvement, 187
 economic approaches, 179-180, 197
 feedback, 183-186
 patient influences, 181-183
 practice profiling, 183-186
- Activities of Daily Living scales, 40
- Acute myocardial infarction
 exclusion of elderly persons in trials, 45
 Physicians' Health Study, 54, 55, 56
 PORT project, 69, 70, 71, 72
 thrombolytic drug trials, 51-53, 55, 57, 178
- Administrative approaches to changing physician behavior, 180-181, 197
- Adolescents. *See also* Infants and children
 preventive services, 221
 scoliosis-related morbidity, 156-157, 158, 224-225
- Adrenoleukodystrophy
 Lorenzo's oil treatment, 45
- Advisory Committee on Immunization Practices
 clinical practice guidelines, 146, 150, 167, 221-223
- Aetna Life and Casualty Co.
 ABMTHDC trial support, 94
 technology assessment activities, 138, 141
- African Americans
 coronary bypass surgery data, 47
- Agency for Health Care Policy and Research. *See also* Patient Outcomes Research Teams
 activities chart, 13, 136
 BPH trial funding, 84
 budget, 97
 clinical algorithms, 155
 clinical practice guidelines, 2, 9-10, 140-141, 143, 145, 150, 155, 164, 166, 168, 211-214
 comparative effectiveness studies, 82
 components, 96
 cost-effectiveness considerations, 122, 154
 creation of, 2, 23, 34, 73, 96, 135
 evidence rating systems, 156
 Forum for Quality and Effectiveness in Health Care, 140
 guidelines dissemination, 190, 191
 incorporating quality of life measurements into trials, 43
 mandate, 2, 39, 73, 96, 135, 140
 Medical Treatment Effectiveness Program, 33-34, 97
 RCT funding, 7
 research coordination efforts, 102-104
 role, 33, 34
 sharing of information with NIH, 84-85
 use of patient representatives on guidelines panels, 155
- AHA. *See* American Heart Association
- AHCPR. *See* Agency for Health Care Policy and Research
- AIDS. *See also* HIV
 clinical trials registry, 86
 experimental treatments, 181
 large, simple trials to identify effective treatment, 55
 procedure volume relationship to patient outcome, **29**
 SF-36 quality-of-life scale use in trials, 83
 surrogate endpoint use in drug trials, 91
 zidovudine treatment study, 83
- ALD. *See* Adrenoleukodystrophy

296 | Identifying Health Technologies That Work

- ALLHAT clinical trial of hypertension and cholesterol-lowering treatments, 85, 87
- AMA. *See* American Medical Association
- Ambulatory Sentinel Practice Network, 88-89
- American Academy of Family Practice, 88
- American Academy of Pediatrics
immunization recommendations, 169
infectious disease control monograph, 225-226
statement on appropriate use of tetracycline, 30
- American Cancer Society
colorectal cancer screening, 166
- American College of Cardiology
clinical practice guidelines, 192
- American College of Physicians
Clinical Efficacy Assessment Project, 135, 146, 150, 151, 164, 226-228
clinical practice guideline process, 226-228
colorectal cancer screening, 166
Medical Necessity Program cooperation, 139
technology assessment activities, 141
- American College of Radiology
Medical Necessity Program cooperation, 139
- American College of Surgeons
Medical Necessity Program cooperation, 139
- American Diabetes Association
collaboration with CDC's ACIP, 221
- American Gastroenterological Association
colorectal cancer screening, 166
- American Heart Association
clinical practice guidelines, 192
- American Hospital Association
new technologies commentary periodical, 138
- American Lung Association
collaboration with CDC's ACIP, 221
- American Medical Association
clinical practice guidelines, 36, 229-231
Diagnostic and Therapeutic Technology Assessment Program, 136-137, 146-147, 150, 151, 153, 229-231
Directory of Practice Parameters, 139
opposition to NCHCT standards, 134
Practice Parameter Update, 229
technology assessment activities, 141
Teflon® treatment for urinary incontinence, 170
- American Psychological Association
and AHCPR'S depression guidelines, 152
- American Society for Gastrointestinal Endoscopy
colorectal cancer screening, 166
- American Society of Anesthesiologists
anesthesia monitoring guidelines, 193-194
- American Society of Hospital Pharmacists
study of controlled formularies, 126
- American Urological Association
BPH trial funding, 84
- AM I. *See* Acute myocardial infarction
- Anesthesia monitoring guidelines, 193-194
- Anisoylated plasminogen-activator complex
acute myocardial infarction treatment, 52-53
- Annals of Internal Medicine*, 227, 228
- Appropriateness of care
"appropriate" definition, 30-31
cost of care and, 5
RAND study, 30-33, 154, 168
- APSAC. *See* Anisoylated plasminogen-activator complex
- Arthritis
knee replacement surgery for elderly persons, 71
opinion leaders influence on treatment, 183
patient education, 181
- Aspirin
role in preventing heart attacks, 54, 55, 56
- ASPEN. *See* Ambulatory Sentinel Practice Network
- Asthma
clinical practice guidelines, 146, 217, 218
- Australia
CEA standardization efforts, 128
- Autologous bone marrow transplant with high-dosage chemotherapy, 93, 94, 181
- AZT. *See* zidovudine
- ### B
- Back injuries
hospitalization for, 27
- Back pain
PORT project, 69, 70, 72
surgical treatment, 184-185
video disc for patient education, 182
- Bakketeig
firms trial study, 59
- Basic tools for measuring health status and outcomes
attributes, 40
mortality, 40
patient self-assessment and, 40-41
quality of life measurements, 41-42
- Bayesian approach to meta-analysis, 64
- Benign prostatic hyperplasia. *See also* Prostate disease
clinical trials funding, 83
comparative outcomes of procedures, 51
mortality rates, 49
patient education efforts, 181-182
patient self-assessment, 40
PORT project, 84-85, 157
treatment study, 28-29
- Beta-Blocker Heart Attack Trial
per-patient cost, 54
- Beta-blocking drugs
use after heart attack, 50, 54

- Beta-carotene
cancer prevention role, 54, 55, 56
- Blue Cross and Blue Shield Association
ABMT/HDC trial support, 94
clinical practice guidelines in Illinois, 36
cooperative effort with Kaiser Permanence Medical Care Program, 138, 143
Medical Necessity Program, 138, 139
Technology Evaluation and Coverage program, 138, 139
- Bone marrow transplant. *See* Autologous bone marrow transplant with high-dosage chemotherapy
- BPH. *See* Benign prostatic hyperplasia
- Breast cancer
ABMT/HDC treatment, 93, 94, 181
age-specific survival rate study, 64
Brown and Fintor CEA for early detection, 112-113
mammography screening CEA, 123
meta-analysis of alcohol in relation to, 62
- Brown and Fintor
CEA for early detection of breast cancer, 112-113, 115
- Byar
database study criticism, 46
- C**
- Califonia
use of clinical practice guidelines, 36
- Canada
CEA standardization efforts, 128-129
Cesarean delivery rate compared with United States, 193
clinical practice guidelines, 36
- Cardiac angiography
osmolality of radiographic material, 117
- Cardiac pacemakers
decreased use of, 192-193
- Cardiac surgery
mortality data, 186
- Carotid endarterectomy
appropriateness of, 30, 32
mortality following, 47, 165
- Cataracts
AHCPR'S clinical practice guidelines, 152, 213
PORT project, 68, 69, 71, 72, 74, 82
retinal detachment and, 48-49, 71, 72, 74, 82
- CCOP. *See* Community Clinical Oncology Program
- CDC. *See* Centers for Disease Control and Prevention
- CEA. *See* Cost-effectiveness analysis
- CEAP. *See* Clinical Efficacy Assessment Project
- Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices, 146, 150, 167, 221-223
components, 100
cost-effectiveness analyses, 123-124
how-to manual on decision analysis, cost measurement, and CEA, 123
mission, 13, 99
Morbidity and Mortality Weekly Report, 166-167, 221
prevention effectiveness focus, 99-100
vaccination recommendations, 140
- Cesarean delivery. *See also* Pregnancy
clinical practice guidelines, 164
current practice profile, 185
rate comparison in United States and Canada, 193
rates in managed care settings, 179
- Chalmers and colleagues
meta-analysis reliability study, 61-62, 63
- CHAMPUS insurance program, 135
- Chassin
practice variation, 37
- Children. *See* Infants and children
- Chlamydia trachomatis guidelines, 221
- Cholesterol reduction
ALLHAT study, 87
clinical practice guidelines, 146, 217, 218
meta-analysis study, 62
- CIGNA Corp.
ABMT/HDC trial support, 94
technology assessment division, 138
- Cleveland Health Quality Choice Project
report card program, 24
- Cleveland Metropolitan General Hospital
firms trial example, 57
- Clinical algorithms, 147, 148, 150, 155, 161, 232-233
- Clinical-economic trials
"blinding" of patients and physicians, 116-117
clinical protocol influence on resource use, 116-117
cost measurement difficulties, 118
cost variability and sample size, 117-118
examples, 117
generalizability, 118
goals, 116
- Clinical Efficacy Assessment Project
ACP project for internal medicine, 135
clinical practice guidelines, 146, 150, 151, 226-228
evidence basis for guidelines, 164
Clinical management guidelines, 195

298 | Identifying Health Technologies That Work

- Clinical practice guidelines. *See also* appendix C; Physician behavior; *specific federal government agencies and private organizations by name*
- 'basis for recommendations, 164-166
 - clinical algorithms, 147, 148, 150, 155, 161, 232-233
 - core tasks descriptions, 210-236
 - cost and cost-effectiveness issues, 153-154
 - defensive medicine and, 35
 - definitions, 24-26, 139-140
 - development-related issues overview, 147, 149
 - federal efforts, 9-11, 145-146
 - group interaction and decisionmaking techniques, 11, 157-164
 - guideline implementation, 190-197
 - guideline panel selection, 151-153
 - identifying and synthesizing evidence, 155-157
 - impact of guidelines on practice, 173-198
 - link between methods and recommendations, 168-169
 - malpractice insurance and, 35
 - methodological research, 11, 15.168
 - model for basing health insurance benefits on, 36
 - organization and administration of guideline activities, 166-168
 - overlap of recommendations, 168-169
 - patient health status and functioning, 154-155
 - patient preferences, 155
 - policy options, 15-16
 - prioritizing guideline topics, 169-170
 - private efforts, 146-147
 - research needs, 170-171
 - scope, 153-155
 - state legislative activities, 35
 - support for, 34
 - technology assessment and, 9-10, 139-141
 - topic selection criteria, 149-151
- Clinton administration
- effectiveness and cost-effectiveness research and, 36
 - health care reform proposal, 34
 - insurance coverage of new and experimental technologies, 92
- Cochrane, Archie
- randomized controlled trials, 19-20
- Cochrane Collaboration
- centers, 81
 - database development, 171
 - features, 79-80
- Codman, Earnest A.
- patient outcomes research, 19
- Colonoscopy
- rates of, 186
- Colorectal cancer
- screening for, 166-167
- Combinability of results issue in meta-analysis, 62-63
- Community-based research
- administrative barriers, 88
 - examples, 87-90
- Community Clinical Oncology Program, 88
- Comparability of cost-effectiveness analyses, 112-114
- Comparative effectiveness trials, 82-83
- Comparative uses of administrative databases, 48-51
- Congestive heart failure
- digitalis treatment, 55, 82-83
 - hospital length-of-stay guidelines, 194-195
- Connecticut
- geographic variation in inpatient care utilization, 27
 - hospitalization rates for back injury, 27
- Consensus Development Conference Program of NIH
- basis for guidelines, 164
 - clinical practice guidelines process, 214-217
 - direct mailings, 190
 - establishment of, 133
 - hearing impairment screening for infants, 153
 - methodology of research, 168, 170
 - physician practice change, 190, 192
 - public forums, 155
 - purpose, 141, 146
- Continuous quality improvement, 187, 198
- Coronary angiography
- geographic variation in use, 32
- Coronary artery disease
- treatment comparison, 49-50
- Coronary bypass surgery
- rates for African Americans, 47
- Cost-benefit analysis
- description, 108
- Cost-effectiveness analysis
- analytic approaches, 107-108
 - clinical-economic trials, 116-118
 - comparability issue, 8, 112-114
 - conclusions, 127-130
 - cost-utility analysis, 118-122
 - definition, 23-24
 - description, 7, 108
 - federal activities, 9, 13, 122-125
 - international standardization efforts, 128-129
 - mechanics of, 110-111
 - models for, 111
 - origins, 109
 - policy options, 14
 - private sector activities, 8, 125-127
 - purposes, 108-109
 - quality issue, 114-115
 - technology assessment comparison, 132

- uses of, 108-110
 - Cost-Effectiveness Panel on Clinical Preventive Services
 - ODPHP sponsorship of, 101
 - Cost-utility analysis
 - advantages, 118-119, 127
 - dangers of, 120-121, 127-128
 - description, 8, 108
 - distributional considerations, 120-121
 - measuring utilities, 119-120
 - social decisions and, 121
 - Council on Health Care Technology Assessment
 - establishment, 134-135
 - CQI. *See* Continuous quality improvement
 - CRC. *See* Colorectal cancer
 - CUA. *See* Cost-utility analysis
- D**
- Daniels and Schroeder
 - patient outcomes research, 28
 - Database studies
 - comparative uses, 48-51
 - contributions, 74-75
 - descriptive uses, 46-48
 - RCT comparison, 5, 46
 - DATTA. *See* Diagnostic and Therapeutic Technology Assessment Program
 - Davis and colleagues
 - strategies to change physician behavior, 189-190
 - Decision analysis
 - advantages and disadvantages, 65-66, 75
 - description, 65, 162-163
 - Decision support systems, 159-162
 - Decisionmaking
 - factors, 175-177, 178
 - group interaction and, 159-162
 - models, 173-175
 - rules and procedures, 162-163
 - Defensive medicine
 - clinical practice guidelines and, 35
 - Delphi technique, 159, 160-161, 171, 233, 235-236
 - Department of Defense
 - CHAMPUS insurance program, 135
 - research role, 21
 - Department of Health and Human Services. *See specific agencies by name*
 - Department of Veterans Affairs. *See also* Veterans Health Administration
 - BPH trial funding, 84-85
 - clinical trials registry, 86
 - comparative effectiveness studies, 82
 - Health Services Research & Development Service, 102
 - Medical Research Service, 82, 88, 102
 - Prostate Cancer Intervention Versus Observation Trial, 82
 - Rehabilitation Research and Development Service, 102
 - role, 13, 21
 - Depression
 - American Psychological Association's disagreement with AHCPR'S guideline, 152
 - patient outcome effect, 30
 - DES. *See* Diethylstilbestrol
 - Descriptive uses of administrative databases, 46-48
 - Detailing form of peer influence, 183
 - Diabetes
 - insulin therapy trial, 46
 - laser treatments for diabetic retinopathy, 178-179
 - patient involvement in treatment, 181
 - Diagnostic and Therapeutic Technology Assessment Program
 - clinical practice guidelines, 146-147, 150, 151, 153, 229-231
 - establishment of, 136-137
 - Dickersin and Berlin
 - meta-analysis studies, 62
 - Diethylstilbestrol
 - inadequate research example, 20, 78
 - Digitalis
 - congestive heart failure treatment, 55, 82-83
 - per-patient cost of study, 54
 - Dingell, Rep. John, 3, 199
 - Directory of Practice Parameters*, 139
 - Drug prescribing guidelines, 195. *See also* Food and Drug Administration; Pharmaceutical companies
 - Duke Database for Cardiovascular Disease, 49-50
- E**
- Ear infections
 - acute ear infection management trial, 103
 - Economic approaches to changing physician behavior, 179-180, 197
 - ECRI
 - clearinghouse activities, 138
 - Eddy
 - clinical practice guideline definition, 139-140
 - Effectiveness research. *See also* Cost-effectiveness analysis
 - appropriateness of care, 5, 30-33
 - clinical research infrastructure improvement, 87-90
 - comparative evaluation of new technologies, 90-95
 - comparative trials, 82-83
 - conclusions, 37-38, 104-105
 - definition, 23
 - federal funding and support, 4-5, 13, 95-104

300 | Identifying Health Technologies That Work

- federal medical treatment effectiveness program, 33-34
 - gaps in existing federal effort, 77-95
 - geographic variations in medical practice. 26-28
 - health care reform and, 34-37
 - history, 26
 - ongoing trials registry, 85-87
 - patient outcomes, 28-30
 - quality-of-life assessment inclusion, 83-85
 - research coordination, 102-104
 - systematic reviews, 78-82
- Efficacy and effectiveness comparison, 23
- Elderly persons
- arthritis and, 71
 - CEA of community-based care. 122
 - exclusion of in AMI trials, 45
 - knee replacement surgery PORT, 71
 - Medicare claims to estimate costs of health care, 46
 - Pap screens study, 111
- Eli Lilly and Co.
- cost-effectiveness analyses, 126
- Emphysema
- surgical treatment, 22
- European Union
- CEA standardization efforts, 129
- EuroQol index, 42
- Evaluation of efficacy and safety
- DES example, 20
 - federal government role, 20-21
 - reasons for public lack of understanding, 21
 - surgical technique examples, 22
 - terminology, 23-26
- Experimental studies
- description, 43-46
- Experimental technologies. *See* Insurance coverage of new and experimental technologies
- F**
- FDA. *See* Food and Drug Administration
- Fecal occult blood testing
- colorectal cancer screening, 166
- Federal government. *See also specific agencies by name*
- cost-effectiveness activities, 122-125
 - directing and coordinating activities, 16-17
 - effectiveness research, 33-34, 77-105
 - guideline activities, 210-225
 - health technology assessment role, 2-3, 13-17, 131-135
- Feedback influence on physician behavior, 183-187, 198
- Femur fracture
- procedure volume relationship to patient outcome, 29
- Firms trials
- advantages. 57
 - applications, 7, 58-59
 - basic concepts, 57
 - community-based research possibility, 89-90
 - limitations, 57-58
 - methodological issues, 58
- Food and Drug Administration
- medical device evaluation, 91
 - meta-analysis uses. 64
 - new technology evaluation role, 91-92
 - review of cost-related claims in drug advertising, 9, 127
 - role, 21
 - surrogate endpoints in drug trials, 91
 - transition of drugs from prescription to over-the-counter, 92
- Formularies, 126, 180
- Forum for Quality and Effectiveness in Health Care, 140
- Foundation for Informed Medical Decisionmaking
- video disc technology for patient education, 181-182
- G**
- Gallstone lithotripsy
- CEA of. 122
- General Accounting Office
- meta-analysis uses, 64
- Geographic variation in medical practice
- appropriateness ratings and, 31-33
 - high-cost procedure use, 179-180
 - surgical procedure studies, 26-28
- GISSI. *See* The Gruppo Italiano per lo Studio della Streptochinasi Nell' Infarto Miocardio
- Glaxo, Inc.
- cost-effectiveness analyses, 126
- Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 52-53
- Glover
- tonsillectomy study, 26
- GM-CSF. *See* Granulocyte macrophage colony stimulating factor
- Granulocyte macrophage colony stimulating factor
- Hodgkins disease adjuvant therapy, 117
- Grassley, Sen. Charles E., 3, 199
- Group interaction and decisionmaking
- decision support systems, 159-162
 - formal group processes, 159

- The Gruppo Italiano per lo Studio della Streptococcal Infarction in the Myocardium (GISSI) Study, 52-53, 75, 87
Guide to Clinical Preventive Services, 146, 224, 225
 GUSTO. *See* Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
- H**
- Hadorn
 model for basing health insurance benefits on, 36
- Harvard Community Health Plan
 clinical algorithms, 147, 148, 150, 155, 232-233
 clinical practice guidelines process, 231-234
 cost-effectiveness considerations, 154
 CQI methods to change practice, 187, 188
 methodology of research, 168
- Hatch, Sen. Orrin, 3, 199
- HCFA. *See* Health Care Financing Administration
- HCHP. *See* Harvard Community Health Plan
- Health Care Financing Administration
 administration of Medicaid and Medicare programs, 101, 124
 basis for guidelines, 164
 cost-effectiveness analyses, 13, 124-125
 database studies, 50-51
 linkage of SEER-Medicare databases, 101
 Office of Research and Demonstrations, 101
 purpose, 13, 124
- Health care reform
 effectiveness research and, 34-37
- Health effects evaluation techniques
 basic tools, 40-43
 primary studies, 43-59
 secondary techniques, 59-67
- Health Industry Manufacturer's Association
 opposition to NCHCT standards, 134
- Health Insurance Association of America
 payment for new and experimental treatments, 93
 technology assessment activities, 138-139
- Health maintenance organizations. *See also specific organizations by name*
 collaborative effort on prevention strategies, 100
 controlled formularies, 126
- Healthy People 2000* report, 101
- Health technology assessment
 definitions, 9, 131-132
 federal efforts, 9-10, 15, 131-135
 organizations involved in health technology assessment activities, 137
 origins of, 133
 private sector efforts, 9, 135-139
 transition from public to private sector, 141-142
- Health Utilities Index, 42
- Hearing impairment screening for infants, 153
- Heart attack. *See* Acute myocardial infarction
- Henry and Wilson
 meta-analysis reliability study, 61
- Hepatitis B vaccines
 cost-effectiveness study, 115
- Hershey and colleagues
 firms trials study, 58
- High blood pressure. *See* Hypertension
- Hip fracture
 PORT project, 72
- Hip replacement
 clinical-economic trial of hospitalization after, 117
- HIV
 AHCPR guideline, 212, 213, 214
- HMO Group
 TEMINEX technology assessment project, 138
- HMOs. *See* Health maintenance organizations
- Hodgkins disease
 clinical-economic trial on benefits of GM-CSF, 117
- Hospital Association of New York
 technology assessment manual for hospitals, 138
- Hospitalization
 for back injury, 27
 geographic variation in inpatient care utilization, 27
 length-of-stay guidelines, 194-195
 Medicaid prescription drug reimbursement limits, 180-181
 for pneumonia, 71-72
 relationship to physician reimbursement, 179
- Human immunodeficiency virus. *See* HIV
- Hypertension
 clinical practice guidelines, 146, 217, 218
 comparative effects of treatments study, 83, 85
- Hysterectomy rates
 efforts to reduce, 183, 184-186
 geographical variation, 26-27
- I**
- ICUs. *See* Intensive care units
- Illinois
 Blue Cross and Blue Shield clinical practice guidelines, 36
 Mt. Sinai Hospital Cesarean delivery rates, 193
- Immunizations. *See also* Vaccinations
 American Academy of Pediatrics recommendations, 169
 CDC recommendations, 146, 150, 167, 221-223
- Impact of guidelines on practice
 active approaches to changing behavior, 179-187
 factors influencing, 195-197
 guideline implementation, 190-197

302 I Identifying Health Technologies That Work

- literature on physician behavior change, 187, 189-190, 198
 - passive approaches to changing behavior. 177-179, 198
 - physician behavior, 173-177
- Indiana
- Reganstrief Health Center firms trials study, 58-59
- Infants and children. See also Adolescents; Cesarean delivery: Pregnancy
- acute ear infection management trial, 103
 - community-based research, 89
 - hearing impairment screening, 153
 - immunization recommendations, 169
- Informed consent, 181
- Institute of Medicine
- clinical practice guidelines, 34, 139, 140, 141, 142, 150
 - cost-effectiveness considerations, 154
 - Council on Health Care Technology Assessment, 134-135
 - database studies, 47
 - Medical Technology Assessment Dirt' ctory*, 136, 138
- Insurance coverage of new and experimental technologies. See also *specific insurance companies by name*
- autologous bone marrow transplant with high-dosage chemotherapy example, 93, 94
 - concerns, 94, 95
 - "medically necessary" definition, 92-93
- Intensive care units
- length-of-stay guidelines, 194-195
- Intermountain Health Systems
- CQI methods to change practice, 187, 188
- International Study of Infarct Survival, 51-53, 87
- IOM. See Institute of Medicine
- ISIS. See International Study of Infarct Survival
- Italy
- acute myocardial infarction study, 52-53, 75, 87

J

- JCAHO. See Joint Commission on Accreditation of Healthcare Organizations
- Jefferson and Demichelli
- literature review on cost-effectiveness of *hepatitis B* vaccines, 115
- Joint Commission on Accreditation of Healthcare Organizations
- Indicator Monitoring System, 25

K

- Kaiser Permanence Medical Care Program
- cooperative effort with Blue Cross and Blue Shield Association, 138, 143
 - report card project, 25
- Karnofsky Index, 40
- Kennedy, Sen. Edward, 3, 199
- Klawansky and colleagues
- meta-analysis study, 64
- Knee replacement surgery
- PORT project, 71

L

- Large, simple trials
- characteristics, 51
 - current applications, 7, 55, 57
 - GISSI example, 52-53, 75, 87
 - head-to-head comparisons of treatments, 53
 - implications and limitations, 53-55, 75
 - ISIS example, 51-53, 87
 - need for simplicity in design, 54-55
 - per-patient cost advantage, 54
- Laser capsulotomy. See Cataracts
- Lau, Antman, and colleagues
- AMI meta-analysis, 78
- Law and colleagues
- meta-analysis study of reducing cholesterol, 62
- Leonard Davis Institute
- CEA guidelines development, 127
- Lidocaine
- in myocardial infarction treatment, 49, 50, 78-79
- "Linking Medical Evidence with Clinical practice" workshop, 201, 204
- Lomas and colleagues
- Cesarean delivery rate comparison, 193
- Longitudinal Comparisons of Measures for Health Outcomes, 122
- Lorenzo's oil, 45
- Luft and colleagues
- procedure volume relationship to patient outcome, 29
- Lusted
- decision analysis paper, 65

M

- Maine
- back surgery PORT, 70
 - clinical practice guidelines legislation, 35
 - hospitalization rates for back injury, 27
 - surgical procedure reduction study, 184-185

- Maine Medical Assessment Foundation, 184-185
- Malpractice insurance
clinical practice guidelines and, 35
- Mammography
CEA of breast cancer screening, 123
- Markov model
use in cost-effectiveness analysis, 111
- Maryland
clinical practice guidelines legislation, 35
Cochrane Collaboration center, 81
insurance coverage of new and experimental technologies, 92
- Maryland Quality Indicator Project
report card program, 24
- Mason and colleagues
comparative study of cost per QALY of medical technologies, 113-114
- Massachusetts
anesthesia monitoring guidelines, 193-194
geographic variation in inpatient care utilization, 27
- Matchar
benefits of decision analysis, 65
- Medical devices
FDA role in evaluating, 91.132-133
- Medical Necessity Program, 138, 139
- Medical Outcomes Study, 29-30, 41, 42
- Medical school curricula
decisionmaking training, 190
- Medical Technology Assessment Directory*, 136, 138
- Medical Treatment Effectiveness Program, 33-34, 97
- Medicare. *See also* Health Care Financing Administration
database studies, 51
diagnosis-based payment for inpatient services, 179
effort to link with SEER registry, 99
use of claims data to estimate costs of health care
for elderly persons, 46
utilization reviews, 190
- MEDLINE®
AIDS treatment trials, 86
augmented clinical trials database for, 82
constraints, 81
- MEDTEP. *See* Medical Treatment Effectiveness Program
- Meta-analysis. *See also* Systematic reviews
Bayesian approach, 64
characteristic, 59-61
combinability of results issue, 62-63
cross-design syntheses, 64
fixed effects model, 63
nine steps of, 60-61
pooled analyses comparison, 61
protocol issue, 63-64
publication bias issue, 63
random effects model, 63
topics for, 64
- MetaWorks, Inc.
activities, 138
- MetropolitanLife Insurance Co.
ABMT/HDC trial support, 94
- Minnesota
clinical practice guidelines legislation, 35
technology assessment consensus document, 138
- MMAF. *See* Maine Medical Assessment Foundation
- Morbidity and Mortality Weekly Report*, 166-167, 221
- MOS. *See* Medical Outcomes Study
- Mt. Sinai Hospital (Chicago) Cesarean delivery rates, 193
- Multiple sclerosis
newly approved drug for, 182
- N**
- National Association of Insurance Commissioners
working group on payment for new and experimental treatments, 93
- National Asthma and Prevention Education Program, 217, 218
- National Cancer Institute
ABMT/HDC trial, 93, 94
clinical-economic study funding, 117
clinical practice guidelines, 146, 150, 164, 167, 219-221
colorectal cancer screening, 166
community-based research, 88
cost-effectiveness considerations, 123, 154
database studies, 50
PDQ database, 86, 146, 154, 167-168
screening: recommendations, 140
SEER registry, 99
supportive cancer care, 154
- National Center for Health Care Technologies.”
133-134
- National Center for Health Services Research
clinical-economic studies, 117
Office of Health Technology Assessment, 134
outcomes research program, 33
- National Center for Health Statistics, 100”
- National Center for Nursing Research, 99
- National Cholesterol Education Program, 217, 218
- National Committee for Quality Assurance
report card project, 25
- National Eye Institute
ongoing studies, 99
quality-of-life measurements, 83, 84

304 I Identifying Health Technologies That Work

- National Foundation for Infantile Paralysis
 - polio vaccine study, 51
 - National Health Information Center, 101
 - National Heart, Lung, and Blood Institute
 - basis for guidelines, 164
 - cholesterol, asthma, and blood pressure guidelines, 140
 - clinical practice guidelines, 146, 150, 151, 167, 217-219
 - cost-effectiveness analyses, 123
 - digitalis treatment study, 55,82-83
 - literature reviews, 155
 - patient representatives, 155
 - National High Blood Pressure Education Program, 217, 218
 - National Institute for Allergies and Infectious Disease
 - incorporation of quality -of-] ife measurements in trials, 83
 - National Institute for Child Health and Human Development
 - acute ear infection management trial, 103
 - meta-analysis study, 79
 - National Institute of Mental Health
 - CEA studies, 123
 - co-sponsorship of schizophrenia PORT, 103
 - National Institute on Aging
 - cost-effectiveness analyses, 123
 - National Institutes of Health. *See also* Consensus Development Conference Program; Office of Medical Applications of Research; *specific institutes by name*
 - activities, 13
 - BPH trial funding, 84-85
 - budget, 97,98
 - clinical trials registry, 86-87
 - comparative effectiveness studies, 82
 - components, 98
 - cost-effectiveness activities, 122-123
 - database development, 171
 - effort to link Medicare with SEER registry, 99
 - features of studies. 97,99
 - incorporating quality of life measurements into trials, 43
 - role, 20-21
 - sharing of information with AHCPR, 84-85
 - trialsponsorship, 79, 82
 - use of quality-of-life measurements, 83-84
 - National Library of Medicine, 81, 171,212
 - NCHCT. *See* National Center for Health Care Technologies
 - NCHSR. *See* National Center for Health Services Research
 - NEI. *See* National Eye Institute
 - New technology evaluation. *See also* Insurance coverage of new and experimental technologies
 - avenues for enrollment in comparative evaluations, 90
 - enhancing number and quality of, 90-91
 - FDA role, 91-92
 - New York
 - cardiac surgery outcomes data, 24
 - Health Department's cardiac bypass surgery data form, 186
 - NHLBI. *See* National Heart, Lung, and Blood Institute
 - NICHHD. *See* National Institute for Child Health and Human Development
 - NIH. *See* National Institutes of Health
 - NIMH. *See* National Institute of Mental Health
 - NLM. *See* National Library of Medicine
 - Nominal Group Technique, 159
 - Norway
 - health care priorities study, 121
 - Nottingham Health Profile, 42
- O
- Observational studies
 - description, 43
 - Odone, Augusto and Michaela, 45
 - Office of Disease Prevention and Health Promotion.
 - See also* U.S. Preventive Services Task Force
 - activities, 13, 100-101
 - budget, 100
 - cost-effectiveness analyses, 125
 - Healthy People 2000* report, 101
 - Office of Health Technology Assessment
 - health technology assessment activities, 133
 - policy options, 15
 - proposal to augment funds with private funds, 135
 - purpose, 134, 143
 - Office of Malaria Control in War Areas, 99
 - Office of Medical Applications of Research, 86, *See also* Consensus Development Conference Program
 - clinical guideline process, 146, 150
 - establishment of, 133
 - Office of Technology Assessment
 - health technology assessment activities, 133
 - purpose of, 133
 - study profile, 3, 199-202
 - technology assessment definition, 131-132
 - Ohio
 - Cleveland Metropolitan General Hospital firms trial example, 58
 - Wade Park Veterans Affairs Medical Center firms trial example, 58

- OHTA. *See* Office of Health Technology Assessment
- OMAR. *See* Office of Medical Applications of Research
- Ongoing clinical trials registry
barriers to, 86-87
purposes, 85-86
- Opinion leader's influence on physician behavior, 183
- Oregon
prioritization of health care services, 35, 42, 120, 130
- Outcomes-based management. *See also* Patient outcomes"
definition, 23
report cards, I 2, 24-25
- Outcomes research. *See also* Patient outcome"
definition, 23
- P**
- Passive dissemination of information, 177-179, 198
- Patient education, 181-183, 197
- Patient involvement in decision making, 181-183
- Patient outcomes
Medical Outcomes Study, 29-30
physician preferences and uncertainty as factors, 28
procedure volume relationship to outcome, 29
prostate disease research, 28-29
report card programs, 24-25
- Patient Outcomes Research Teams
AHCPR funding, 73, 79
components, 67-68
conference conclusion s." 73
contributions, 6, 68, 70-72, 75-76
cost-effectiveness analysis and, 122
description, 66-67
future plans, 73
goals, 67
interPORT work groups, 68
limitations and frustrations, 72-73
planned and current projects, 69
structure, 67
topics addressed, 67
- Patient reminders, 190, 192
- PDQ database. *See* Physician Data Query database
- Peer influence on physician behavior, 183
- Peripheral artery angioplasty, 47
- Peritonitis
antibiotic treatment of spontaneous bacterial peritonitis, 117
- Pharmaceutical companies
cost-effectiveness analyses, 125-126
marketing directly to patients, 181
- Pharmacoeconomics, 111-112, 125
- Physician behavior
active approaches to changing, 11, 179-187, 198
behavioral models, 173-175, 176
conclusions, 197-198
factors underlying current practices, 11, 175, 177, 178
impact of guidelines on, 190, 192-197, 198
literature on, 187, 189-190
opinion leaders influence, 11, 183
passive approaches to changing, 11-12, 177-179, 198
- Physician Data Query database, 86, 146, 154, 167-168, 220-221
- Physician ownership of facilities, 179
- Physician Payment Review Commission
clinical practice guidelines and, 34
- Physicians' Health Study
description, 56
large, simple trial example, 55
per-patient cost, 54
- PIVOT. *See* Prostate Cancer Intervention Versus Observation Trial
- Pneumonia
PORT project, 71-72
- Poliovaccine, 51
- Pooled analysis
meta-analysis comparison, 61
- PORTs. *See* Patient Outcomes Research Teams
- Practice Parameter Update*, 229
- Practice profiling influence on physician behavior, 12, 183-186, 198
- Pregnancy. *See also* Cesarean delivery
Cochrane Collaboration on premature births, 80
large, simple trials for fetal movement counting, 55
- Preventive care guidelines, 192
- Primary studies to evaluate health effects
categories, 43-46
database studies, 46-51
firms trials, 57-59
large, simple trials, 51-57
- Private sector. *See also specific organizations by name*
cost-effectiveness analysis, 125-127
guideline activities, 225-236
health technology assessment, 9, 135-139
- Procedure volume relationship to patient outcome, 29
- Prospective Payment Assessment Commission, 134
- Prostate Cancer Intervention Versus Observation Trial, 82

306 | Identifying Health Technologies That Work

Prostate disease. *See also* Benign prostatic hyperplasia

CEA of prostate cancer screening, 123

PORT project, 69,70,72, 84-85

screening for, 181

Prostatectomy. *See* Benign prostatic hyperplasia; Surgery; Transurethral prostatectomy

Prudential Insurance Co. of America

ABMT/HDC trial support, 94

technology assessment division, 138

Publication bias issue in meta-analysis, 63

Q

QALYs. *See* Quality-adjusted life years

Quality-adjusted life years

inconsistencies in measurement and use of, 113, 115-116

value of life, 121

Quality of cost-effectiveness analyses, 114-115

Quality-of-life measurements

applications and limitations, 42-43

incorporating in clinical trials, 83-85

Quality of Well Being Scale, 41,42, 119

Quinidine

FDA trial, 91-92

QWB Scale. *See* Quality of Well Being Scale

R

RAND Corp.

Academic Medical Center Consortium cooperative effort, 234

appropriateness of care, 30-33, 154, 168

basis for guidelines, 164

clinical practice guidelines, 141, 147, 153, 234-236

cost-effectiveness considerations, 154

decisionmaking support, 160-161, 163

Delphi group process method, 171,233,235-236

Health Insurance Experiment, 179

ratings of appropriateness, 31

Randomized controlled trials

AHCPR funding, 7

criticisms of, 44-46

database study comparison, 46

description, 43-44

impact on physician behavior, 178

internal validity, 44

underuse in government's effectiveness initiative, 6-7,74-75

Ray and colleagues

tetracycline appropriateness study, 30

RCTS. *See* Randomized controlled trials

Reganstrief Health Center

firms trials study, 58-59

Report cards for patient outcomes, 12,24-25

Rhode Island

surgery rates, 27

Risk Management Foundation of Harvard Medical Institutions

anesthesia monitoring guidelines, 193-194

Roper, William

effectiveness research proposal, 33

Rubin

meta-analysis study characteristics, 63-64

S

Salivary glands

surgery to protect glands during radiation therapy, 22

Salk polio vaccine study, 51

Schizophrenia

PORT project, 103

Scoliosis

morbidity among adolescents, 156-157, 158, 224-225

Secondary techniques to synthesize research results

decision analysis, 65-67

meta-analysis and other systematic reviews, 59-65

SEER registry. *See* Surveillance, Epidemiology and End Results registry

Sexually transmitted diseases. *See also* AIDS; HIV clinical practice guidelines, 221

SF-36 patient functioning questionnaire, 30,41,42, 83

Sickle cell disease

AHCPR guideline, 212

Sickness Impact Profile, 41, 42,83

SIP. *See* Sickness Impact Profile

Soumerai and colleagues

feedback and reminder systems study, 190

Spain

CEA standardization efforts, 129

Streptokinase

acute myocardial infarction treatment, 52-53, 55, 57,78

Stroke

PORT project, 71, 120

Surgeon General's Report on Nutrition and Health, 101

Surgery. *See also specific types of surgery by name*

anesthesia monitoring guidelines, 192, 193-194

benign prostatic hyperplasia treatment, 28-29

cardiac surgery mortality data, 186

emphysema treatment, 22

hysterectomy rates, 26-27

to preserve salivary glands during radiation therapy, 22

- procedure volume relationship to patient outcome, 29
 tonsillectomy studies, 26, 27
 wound infection study, 188
 Surveillance, Epidemiology' and End Results registry, 99
 Systematic reviews. *See also* Meta-analysis
 Cochrane Collaboration, 79-81
 contributions, 78-79
 improving efficiency of, 13, 81-82
- T**
- Technology Assessment Group, Inc., 138
 Technology Evaluation and Coverage program, 138, 139
Technology Reports, 138
 Teflon®
 urinary incontinence treatment, 170
 TEMINEX technology assessment project, 138
 Tennessee
 tetracycline appropriateness study, 30
 Terms and definitions, 23-26
 Test ordering guidelines, 195
 Tetracycline
 appropriateness of use study, 30
 Thrombolytic drugs
 effects on acute myocardial infarction, 51-53, 55, 57, 178
 Tissue-type plasminogen activator
 acute myocardial infarction treatment, 52-53, 55, 57
 Tonsillectomy studies, 26, 27, 49
 TPA. *See* Tissue-type plasminogen activator
 Transfusion practice guidelines, 195
 Transurethral prostatectomy
 benign prostatic hyperplasia treatment, 28-29, 84, 157
 mortality rate, 47, 49
 Travelers Corp.
 ABMT/HDC trial support, 94
 Tufts University School of Dental Medicine
 surgery to protect salivary glands during radiation treatment, 22
 TURP. *See* Transurethral prostatectomy
- u**
- Udvarhelyi and colleagues
 fundamental principles of cost effectiveness, 114-115
 United HealthCare Corporation
 report card program, 24, 25
 United Kingdom
 appropriateness of treatment for coronary disease, 152, 165
 coronary angiography and bypass surgery rates compared with United States, 32
 tonsillectomy study, 26
 University Hospitals Consortium
 in-house technology assessment office, 138, 142
 University of Pennsylvania
 Leonard Davis Institute CEA guidelines development, 127
 Upper gastrointestinal tract endoscopy
 geographic variation in use, 32
 Urinary incontinence guidelines, 151, 152-153, 170
 UR. *See* Utilization reviews
 U.S. Healthcare, Inc.
 ABMT/HDC trial support, 94
 report card project, 25
 U.S. Preventive Services Task Force
 clinical practice guidelines, 146, 150, 154, 156, 164, 167, 223-225
 colorectal cancer screening, 166
 Guide to Clinical Preventive Services, 146, 224, 225
 meta-analysis and, 64
 ODPHP sponsorship of, 101
 USPSTF. *See* U.S. Preventive Services Task Force
 Utah
 CQI study, 187, 188
 Utilization reviews, 180, 190
- V**
- VA. *See* Department of Veterans Affairs
 Vaccinations. *See also* Immunizations
 allowing nurses to administer, 180
 CDC recommendations, 140
 Vaccines
 hepatitis B, 115
 polio, 51
 Vermont
 clinical practice guidelines legislation, 35
 tonsillectomy rates, 27
 Vermont Trials Network, 89
 Veterans Health Administration. *See also* Department of Veterans Affairs
 activities, 101-102
 Video disc technology for patient education, 181-182
- W**
- Wade Park Veterans Affairs Medical Center
 firms trial example, 58
 Washington
 back surgery PORT, 70

308 / Identifying Health Technologies That Work

Wennberg and colleagues

- benign prostatic hyperplasia treatment, 28-29
- geographic variation in inpatient care utilization, 27

Women. See *also* Breast cancer; Cesarean delivery;

Pregnancy

- clinical trials registry of studies involving, 86-87
- Pap screens for elderly women study, 111

Women's Health Study

- assessment of serious or unknown side effects, 116
- description, 56

Woolf

- clinical practice guideline definition, 139

Y

Yusuf and colleagues

- large, simple trial design, 54

Z

Zidovudine

- AIDS treatment study, 83